Heart valves from Medtronic, Edwards show "encouraging" results

10/24/2011 | MassDevice.com (Boston)

A U.K. study of 877 transcatheter aortic valve implant procedures done from January 2007 to December 2009 found that patients who received Medtronic's CoreValve had lower death rates, while patients who received Edwards Lifesciences' Sapien device had reduced rates of repeat procedures and pacemaker use. Edwards anticipates FDA clearance for its device soon, while Medtronic expects its device to be available in the U.S. market by 2014.

View Full Article in:

MassDevice.com (Boston)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY